One MDS patient, UPN09 in Cohort 4, with ASXL-1 mutation showed a decrease in the percentage of myeloblasts in the bone marrow, but this was part of the transformation of the case into a high-risk chronic myelomonocytic leukemia-myeloproliferative neoplasm (CMMN-MPN) with an absolute monocyte count 17,600/μL around Cycle 10 (Table 1). The gene discussed is ASXL1; the disease is myeloproliferative disorder.